Viracta Therapeutics Analyst Ratings
Viracta Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a maintained with a price target of $7.00 to $6.00. The current price Viracta Therapeutics (VIRX) is trading at is $0.62, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 860.31% | RBC Capital | $7 → $6 | Maintains | Outperform |
| 10/05/2023 | 1020.36% | RBC Capital | → $7 | Reiterates | Outperform → Outperform |
| 08/15/2023 | 1020.36% | RBC Capital | → $7 | Reiterates | Outperform → Outperform |
| 08/15/2023 | 700.26% | SVB Securities | $10 → $5 | Maintains | Outperform |
| 08/15/2023 | 1500.51% | HC Wainwright & Co. | $10 → $10 | Reiterates | Buy → Buy |
| 07/31/2023 | 1500.51% | EF Hutton | → $10 | Initiates Coverage On | → Buy |
| 07/05/2023 | 1500.51% | HC Wainwright & Co. | $33 → $10 | Reiterates | Buy → Buy |
| 05/10/2023 | 5181.69% | HC Wainwright & Co. | $35 → $33 | Maintains | Buy |
| 05/09/2023 | 1020.36% | RBC Capital | $8 → $7 | Maintains | Outperform |
| 05/08/2023 | 1660.56% | SVB Securities | $11 → $11 | Maintains | Outperform |
| 03/27/2023 | 2460.82% | Oppenheimer | $14 → $16 | Maintains | Outperform |
| 03/14/2023 | 1180.41% | RBC Capital | → $8 | Reiterates | → Outperform |
| 03/14/2023 | 5501.79% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 11/11/2022 | 1180.41% | RBC Capital | $10 → $8 | Maintains | Outperform |
| 11/10/2022 | 1660.56% | SVB Securities | → $11 | Maintains | Outperform |
| 05/03/2021 | 5501.79% | HC Wainwright & Co. | → $35 | Initiates Coverage On | → Buy |
| 04/26/2021 | 2780.92% | SVB Leerink | → $18 | Initiates Coverage On | → Outperform |
| 03/25/2021 | 7102.3% | Evercore ISI Group | → $45 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/10/2023 | 860.31% | 加拿大皇家银行资本 | 7 美元 → 6 美元 | 维护 | 跑赢大盘 |
| 10/05/2023 | 1020.36% | 加拿大皇家银行资本 | → 7 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 08/15/2023 | 1020.36% | 加拿大皇家银行资本 | → 7 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 08/15/2023 | 700.26% | SVB 证券 | 10 美元 → 5 美元 | 维护 | 跑赢大盘 |
| 08/15/2023 | 1500.51% | HC Wainwright & Co. | 10 美元 → 10 美元 | 重申 | 购买 → 购买 |
| 07/31/2023 | 1500.51% | EF Hutton | → 10 美元 | 启动覆盖范围开启 | → 购买 |
| 07/05/2023 | 1500.51% | HC Wainwright & Co. | 33 美元 → 10 美元 | 重申 | 购买 → 购买 |
| 05/10/2023 | 5181.69% | HC Wainwright & Co. | 35 美元 → 33 美元 | 维护 | 买 |
| 05/09/2023 | 1020.36% | 加拿大皇家银行资本 | 8 美元 → 7 美元 | 维护 | 跑赢大盘 |
| 05/08/2023 | 1660.56% | SVB 证券 | 11 美元 → 11 美元 | 维护 | 跑赢大盘 |
| 03/27/2023 | 2460.82% | 奥本海默 | 14 美元 → 16 美元 | 维护 | 跑赢大盘 |
| 03/14/2023 | 1180.41% | 加拿大皇家银行资本 | → 8 美元 | 重申 | → 跑赢大盘 |
| 03/14/2023 | 5501.79% | HC Wainwright & Co. | → 35 美元 | 重申 | → 购买 |
| 11/11/2022 | 1180.41% | 加拿大皇家银行资本 | 10 美元 → 8 美元 | 维护 | 跑赢大盘 |
| 2022 年 10 月 11 日 | 1660.56% | SVB 证券 | → 11 美元 | 维护 | 跑赢大盘 |
| 05/03/2021 | 5501.79% | HC Wainwright & Co. | → 35 美元 | 启动覆盖范围开启 | → 购买 |
| 04/26/2021 | 2780.92% | SVB Leerink | → 18 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 3 月 25 日 | 7102.3% | Evercore ISI 集团 | → 45 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
What is the target price for Viracta Therapeutics (VIRX)?
Viracta Therapeutics（VIRX）的目标价格是多少？
The latest price target for Viracta Therapeutics (NASDAQ: VIRX) was reported by RBC Capital on November 10, 2023. The analyst firm set a price target for $6.00 expecting VIRX to rise to within 12 months (a possible 860.31% upside). 14 analyst firms have reported ratings in the last year.
加拿大皇家银行资本于2023年11月10日公布了Viracta Therapeutics（纳斯达克股票代码：VIRX）的最新目标股价。该分析公司将目标股价定为6.00美元，预计VIRX将在12个月内升至12个月内（可能上涨860.31％）。去年有14家分析公司公布了评级。
What is the most recent analyst rating for Viracta Therapeutics (VIRX)?
分析师对Viracta Therapeutics（VIRX）的最新评级是多少？
The latest analyst rating for Viracta Therapeutics (NASDAQ: VIRX) was provided by RBC Capital, and Viracta Therapeutics maintained their outperform rating.
加拿大皇家银行资本对Viracta Therapeutics（纳斯达克股票代码：VIRX）的最新分析师评级由加拿大皇家银行资本提供，Viracta Therapeutics维持跑赢大盘的评级。
When is the next analyst rating going to be posted or updated for Viracta Therapeutics (VIRX)?
Viracta Therapeutics（VIRX）的下一次分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viracta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viracta Therapeutics was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Viracta Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Viracta Therapeutics的最新评级是在2023年11月10日公布的，因此您应该预计下一个评级将在2024年11月10日左右公布。
Is the Analyst Rating Viracta Therapeutics (VIRX) correct?
分析师对Viracta Therapeutics（VIRX）的评级是否正确？
While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a maintained with a price target of $7.00 to $6.00. The current price Viracta Therapeutics (VIRX) is trading at is $0.62, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Viracta Therapeutics（VIRX）评级维持不变，目标股价为7.00美元至6.00美元。Viracta Therapeutics（VIRX）目前的交易价格为0.62美元，超出了分析师的预期区间。